Across TCGA pan-cancer cohorts, RNVU1-22 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated RNVU1-22 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNVU1-22 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNVU1-22 expression acts as an unfavorable survival marker, although some lineages such as PAAD and READ show a favorable association.
LIHC, ESCA, and CESC are the cancer types where RNVU1-22 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.